Precision Medicine Division Using AI, Big Data and Predictive Technologies Launched
Learn More
NovAccess Global to Present at World Orphan Drug Congress
Learn More
NovAccess Leaders Presented at 2023 SBMT Conference
Learn More
FDA Approves Orphan Drug Designation for TLR-AD1
Learn More
Recent Uplist to OTCQB
Learn More
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
Discovery to Science-Led Public Company
Learn More
Previous
Next
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
The Journey from Discovery to IPO
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
FDA Approves Orphan Drug Designation
Recent Uplist to OTCQB
Recent Uplist to OTCQB
Learn More
Board of Directors Expanded
Patented Immunotherapy Candidate
The Journey from Discovery to IPO
The Journey from Discovery to IPO
Learn More
Previous
Next

Our patented approach, TLR-AD1 seeks to bolster the body’s immune system through cellular training; strengthening the body’s defense against cancer.

Press
All
NovAccess Global Press Releases
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
NovAccess Global to Present at World Orphan Drug Congress
NovAccess Global to Present at World Orphan Drug Congress
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division

With TLR-AD1, we will provide Novel Access to the Global market.

Learn About TLR-AD1

Join Us

Submit